Home > Journals > Journal of Cardiovascular Medicine and Surgery

Journal of Cardiovascular Medicine and Surgery

Submit your article Read this Journals View all journals
Full Text (PDF)
Review Article

PCSK 9 Inhibtors: New Era in Dyslipidemia Management

Debasish Das , Debasish Das , Satyabrata Guru

Author Information

Licence:



Journal of Cardiovascular Medicine and Surgery 1(2):p 75-80, July - December 2015. | DOI:

How Cite This Article:

Timeline

Received : N/A         Accepted : N/A          Published : N/A

Abstract

 Low-density lipoprotein cholesterol (LDL-C) is the most important risk factor for developing coronary artery disease (CAD) as evidenced in landmark INTERHEART study. PCSK9 inhibition offers a novel therapeutic mechanism for lowering low-density lipoprotein cholesterol (LDL-C) levels.PCSK9 is a serine protease that binds the LDL receptor (LDL-R) and acts as a chaperone for endocytosis and shuttling the PCSK9-LDLR complex to lysosomes for degradation. In the absence of PCSK9 the LDLR-LDL-C complex dissociates and LDL-R is recycled back to the cell surface. Humanized monoclonal antibodies against PCSK 9 (evolocumab, alirocumab, bocolicumab) have been developed which increase LDL-R by 2- old and lower LDL-C by up to 75 percent with no significant side effects, with the exception of injection site reactions. These novel agents play a pomising role in filling the therapeutic gap in statin intolerant, difficult dyslipidemics and familial hypercholesterolemic patients. When combined with statins they bring out a better cardiovascular outcome with a stable and target lipid profile. 

References

No records found.


About this article

Cite this article

Licence:



Received Accepted Published
N/A N/A N/A
DOI:

Keywords


Article Level Metrics

Last Updated

Monday 22 June 2026, 11:04:01 (IST)

681

Accesses

1
121
00

Citations


NA
NA
NA

Download citation


Article Keywords

Keyword Highlighting

Highlight selected keywords in the article text.


Timeline

Received N/A
Accepted N/A
Published N/A

licence




Access this article

Reprint Order Form
Buy this Article
Institutional Subscriptions

Share